Cingulate, Inc. Reports Increased Losses Amid R&D Expansion

Cingulate, Inc. ( (CING) ) has released its Q1 earnings. Here is a breakdown of the information Cingulate, Inc. presented to its investors.

Cingulate, Inc. is a biopharmaceutical company specializing in the development of next-generation pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform, primarily targeting Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. In its latest earnings report for the quarter ended March 31, 2025, Cingulate reported a net loss of $3.8 million, an increase from the $3.0 million loss in the same period last year. The company’s operating expenses rose due to increased research and development costs, particularly for its lead product candidate, CTx-1301, and general administrative expenses. Despite the financial losses, Cingulate continues to advance its clinical trials and regulatory submissions, with plans to file a New Drug Application for CTx-1301 in mid-2025. Looking forward, Cingulate aims to secure additional funding to support its operations and commercialization efforts, while it remains focused on achieving regulatory approval and exploring strategic partnerships.